Mesoblast Limited Proprietary Stem Cells For Heart Failure Highlighted At Major Cardiology Conference

This article was originally published here

Melbourne, Nov 11, 2008 (ABN Newswire) – Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the thirteenth patient enrolled in the ongoing Phase 2 clinical trial for congestive heart failure had been safely implanted with the proprietary adult stem cells during a live case at the American Heart Association’s annual conference, currently underway…

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply